International Diabetes Center

Minneapolis, Minnesota 55416

5 studies enrolling now · 51 studies all time

What they study most

Chronic Kidney Disease, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Comparative Effectiveness of Glycemia-lowering Medications, Currently Taking Metformin, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 1, Type 2, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Type 2

Studies at this site

• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Recruiting now
• Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes — Recruiting now
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Recruiting now
• GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes — Recruiting now
• A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes — Recruiting now
• A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes — Completed
• A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9) — Completed
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor — Completed
• A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes — Completed
• Reducing Risk of Diabetic Ketoacidosis in Type 1 Diabetes and Kidney Disease Using Continuous Ketone Monitoring — Starting soon
• A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight — Completed
• Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) — Running, not enrolling
• Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes — Completed
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec — Completed
• A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) — Completed
• Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus — Running, not enrolling
• Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home — Completed
• Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ) — Completed
• Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System — Completed
• The GRADE Capillary Blood Collection Pilot Study — Completed
• FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) — Completed
• A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes — Completed
• Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes — Completed
• Wireless Innovation for Seniors With Diabetes Mellitus — Completed
• Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data — Completed
• Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus — Completed
• Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes — Completed
• Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine — Completed
• Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes — Completed
• Glucose Meter Study — Completed
• Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System — Completed
• Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes. — Completed
• Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes — Completed
• Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide — Completed
• The Impact of Food on Blood Sugar in People With Type 2 Diabetes — Completed
• Characteristics of Persons With an Eating Disorder and Type 1 Diabetes — Completed
• Impact of Continuing Medical Education (CME) Insulin Program — Completed
• Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food — Completed
• Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control — Completed
• Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes — Completed
• Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring — Completed
• Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition — Completed
• Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes — Completed
• Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus — Completed
• An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial — Completed
• Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes — Completed
• Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up — Completed
• Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus — Completed
• Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature — Completed
• Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects — Stopped early